Milan Chheda
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Milan Chheda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03687957 · rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and TemozolomideWashington University School of Medicine · active not recruiting · Glioma · principal investigator
- Ph2NCT03532295 · Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent GliomasWashington University School of Medicine · completed · Glioma, Glioblastoma · principal investigator
- Ph2NCT02781792 · Temozolomide Chronotherapy for High Grade GliomaWashington University School of Medicine · completed · Glioma, Glioblastoma Multiforme · principal investigator
- Ph1NCT01851733 · MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma MultiformeWashington University School of Medicine · completed · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Expand and pull: long-acting IL-7 and oncolytic virus to treat glioblastomaR01CA305974 · NCI · WASHINGTON UNIVERSITY · fiscal years 2026 · $645,185 awarded in 2026Same name and institution; not confirmed by an ID
- Leveraging Zika virus and the immune system to treat glioblastomaR01NS117149 · NINDS · WASHINGTON UNIVERSITY · fiscal years 2021 to 2025 · $401,786 awarded in 2025Same name and institution; not confirmed by an ID
- Understanding how ZFHX4 drives the glioblastoma tumor propagating cell stateR01NS107833 · NINDS · WASHINGTON UNIVERSITY · fiscal years 2018 to 2022 · $344,531 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:59 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.J Neurooncol · 201542 citationsRCR 1.4
- A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys · 202435 citationsRCR 4.3
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nat Cancer · 20265 citationsRCR 2.5